Durvalumab as a Successful Downstaging Therapy for Liver Transplantation in Hepatocellular Carcinoma: The Importance of a Washout Period

Transplantation. 2021 Dec 1;105(12):e398-e400. doi: 10.1097/TP.0000000000003855.

Authors

Miguel Sogbe¹, Diego López-Guerra², Gerardo Blanco-Fernández², Bruno Sangro^{1

3}, Isidoro Narváez-Rodriguez⁴

Affiliations

¹ Liver Unit, Clinica Universidad de Navarra-IDISNA, Pamplona, Spain.
² Department of HBP and Liver Transplant Surgery, University Hospital Complex Badajoz, University of Extremadura, Badajoz, Spain.
³ Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Pamplona, Spain.
⁴ Department of Gastroenterology and Liver Transplant Unit, University Hospital Complex Badajoz, University of Extremadura, Badajoz, Spain.

PMID: 34284418
DOI: 10.1097/TP.0000000000003855

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal / therapeutic use
Carcinoma, Hepatocellular* / pathology
Carcinoma, Hepatocellular* / therapy
Humans
Liver Neoplasms* / drug therapy
Liver Neoplasms* / pathology
Liver Transplantation*
Neoplasm Staging
Treatment Outcome

Substances

Antibodies, Monoclonal
durvalumab